Christina Lewicky Gaupp, MD
Urogynecology and Reconstructive Pelvic Surgery · Chicago, ILNPI 1194844019
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Caldera Medical, Inc at 55.3% of the total. Reporting peaked in 2021 at $2,523 and has fallen 87.5% since, to $316 in 2025.
Across 30 payments — averaging $132.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$2K
- Boston Scientific$1K
- Coloplast$268
- Axonics, Inc.$207
- Intuitive Surgical$99
- Medtronic$67
- plus $116 from 2 others
What the payments were for
- Consulting fees$2,20055%
- Food & beverage$1,77745%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 2 | $2,200 |
| Boston Scientific | 16 | $1,020 |
| Coloplast | 3 | $268 |
| Axonics, Inc. | 3 | $207 |
| Intuitive Surgical | 1 | $99 |
| Medtronic | 3 | $67 |
| Baxter Healthcare | 1 | $65 |
| Applied Medical Resources Corporation | 1 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Desara$2,200
- Advantage System$385
- ALTIS$154
- Solyx SIS System$113
- SOLYX$111
- Axonics$102
How this compares
$3,977 in reported general payments places this provider in the 55th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 57 | $34,054 |
| PremarinEstrogens, Conjugated | 24 | $10,299 |
| MyrbetriqMirabegron | 12 | $6,979 |
| Estradiol | 24 | $1,147 |
| Methenamine Hippurate | 13 | $718 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $337 |
| Ibuprofen | 14 | $41 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Chicago
- Abraham ShashouaChicago$339K
- Akira GillinghamChicago$58K
- Kimberly KentonChicago$43K
- Traci BeckChicago$32K
- Margaret MuellerChicago$26K
- Carol BretschneiderChicago$14K
- Trieu DoChicago$11K
- Sean GeorgeChicago$9K
- Thythy PhamChicago$8K
- Ankita GuptaChicago$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.